News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nicklas Westerholm takes office as CEO of PledPharma and signs 500,000 warrants

June 16, 2017

PledPharma AB
Company Announcement

Nicklas Westerholm takes office as CEO of PledPharma and signs 500,000 warrants

Stockholm, 2017-06-16 08:00 CEST (GLOBE NEWSWIRE) -- 
PledPharma announces that Nicklas Westerholm today assumed the position as the
company's CEO. Nicklas Westerholm comes from AstraZeneca, where he held several
leading global positions in research and development, finance and
manufacturing. In connection with his start, Nicklas Westerholm has acquired
500,000 warrants in PledPharma. 

My initial priority is to ensure the optimal final design of the clinical
development program for PledOx®, and to further strengthen PledPharma's
organization prior execution of the remaining clinical trials. I also look
forward to contributing to the continued development of Aladote®, a potential
drug for preventing liver damage associated with acetaminophen poisoning," said
Nicklas Westerholm, CEO, PledPharma AB. 

PledOx® is the first drug candidate that in a controlled clinical trial has
shown that it may be possible to prevent chemotherapy induced nerve damage
(CIPN) in a clinically significant manner and without negatively effecting the
cancer treatment. A proof of principle study with Aladote® was initiated in
spring 2017 in collaboration with the University of Edinburgh. 

 “With a wholly-owned late stage pharmaceutical project against side-effects
from chemotherapy treatment, and an innovative treatment for
paracetamol-induced liver damage in an ongoing proof of principle study, we
have good opportunities to meet the significant needs of improved treatments
for these severely burdened patient groups in the future. I see this as an
excellent platform for creating good value growth for PledPharmas shareholders,
"continues Nicklas Westerholm. 

Nicklas Westerholm, b. 1976, has since 1995 been working in the AstraZeneca
Group in several global roles and different business areas, most recently as
Vice President Project & Portfolio Management, Cardiovascular and Metabolic
Diseases, Global Medicines Development Unit. Prior positions include roles as
Executive Officer and Vice President of Japan Operations, Director Investor
Relations, Head of Global API Supply and Head of Development Manufacture.
Nicklas Westerholm has studied analytical and organic chemistry at Stockholm
University, and Chemical Engineering at KTH Royal Institute of Technology. He
has also participated in educational programs at the University of Warwick,
INSEAD and Harvard Business School. 

In connection with the appointment as CEO, Nicklas Westerholm has signed
500,000 warrants within the framework of the incentive program decided at the
company's AGM on April 25, 2017. Payment has been made with SEK 1.29 per
warrant. Each warrant jag är entitles the holder to acquire a share in
PledPharma during the period 9-30 November 2020 at the price of SEK 26. The
fully terms and conditions are available on the company's website 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see 

This information is information that PledPharma AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person set out
above, at 08:00 CET on June 16 2017.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10